Posted by Michael Wonder on 14 Aug 2024
FDA approves new drug for hypoparathyroidism, a rare disorder
9 August 2024 - The US FDA has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism.
Yorvipath was not studied in adults with acute post-surgical hypoparathyroidism.
